# Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial

> **NCT04939311** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Priscilla Hsue, MD**

## Conditions studied

- Inflammation
- HIV Infection
- Cardiovascular Disease

## Interventions

- **DRUG:** VB-201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04939311
- **Lead sponsor:** Priscilla Hsue, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding for this trial has not been established.
- **Last updated:** 2022-09-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04939311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04939311, "Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04939311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*